JESSE MAIZELS: Open Payments
NPI 1851986921 · LITTLETON, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,394 in 45 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $126 · 2025 $1,394
Food & beverage: $1,283Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $315 |
| ABBVIE INC. | 10 | $257 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $200 |
| Braeburn Inc. | 4 | $183 |
| Supernus Pharmaceuticals, Inc. | 1 | $126 |
| Alkermes, Inc. | 6 | $109 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Lundbeck LLC | 1 | $25 |
Products named: VRAYLAR, CAPLYTA, BRIXADI, AUSTEDO XR, Qelbree, ARISTADA, UZEDY, REXULTI.
Industry payments across CO — which companies pay providers there.
